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Abstract:  
Introduction: ​The first-line recommended treatment for patients with intermittent claudication          
(IC), is a supervised exercise programme (SEP), which includes a minimum of 2 hours exercise               
per week over a 12-week period. However, provision, uptake, and adherence rates for these SEP               
programmes are poor, with time constraints cited as a common participant barrier. High-intensity             
interval training (HIIT) is more time-efficient and therefore has the potential to overcome this              
barrier. However, evidence is lacking for the role of HIIT in those with IC. This proof-of-concept                
study aims to consider the safety, feasibility, tolerability, and acceptability of a HIIT programme              
for patients with IC. 
Methods and analysis: ​This multi-centre, single-group, prospective, interventional feasibility         
study will recruit 40 patients with IC, who will complete 6 weeks of HIIT, 3 times a week. HIIT                   
will involve a supervised programme of 10x 1-minute high-intensity cycling intervals at 85-90%             
peak power output (PPO), interspaced with 10x 1-minute low intensity intervals at 20-25% PPO.              
PPO will be determined from a baseline cardiopulmonary exercise test (CPET) and it is intended               
that patients will achieve ≥85% of maximum heart rate from CPET, by the end of the second                 
HIIT interval. Primary outcome measures are safety (occurrence of adverse events directly            
related to the study), programme feasibility (including participant eligibility, recruitment and           
completion rates) and HIIT tolerability (ability to achieve and maintain the required intensity).             
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Secondary outcomes include patient acceptability, walking distance, CPET cardiorespiratory         
fitness measures and quality of life outcomes. 
Ethics and dissemination: ​Ethical approval was obtained ​via a local NHS research ethics             
committee (Bradford Leeds – 18/YH/0112) and recruitment began in August 2019 and will be              
completed in October 2020. Results will be published in peer-reviewed journals and presented at              
international conferences and are expected to inform a future pilot randomised controlled trial of              
HIIT versus usual-care SEPs. 
Key Words: ​Vascular Surgery, Rehabilitation medicine, Vascular medicine. 
Current protocol version: ​v1.5 – 15/08/19 
Registration: NCT04042311 
Article Summary: 
Strengths and limitations of this study: 
● This study will assess the safety and feasibility of a novel, pragmatic high-intensity             
interval training programme for patients with intermittent claudication. 
● It will also consider acceptability of the programme via qualitative methods of patient             
feedback. 
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● As a limitation, due to the single-group design it is not possible to identify if patients who                 
choose to take part in this study are simply those who would have also chosen to take part                  
in a usual-care exercise programme. 
 
 
Introduction 
Peripheral arterial disease (PAD) is caused by atherosclerotic lesions in the arteries supplying the              
lower limbs, reducing blood flow (1). PAD is relatively common, age-dependent, and increasing             
in its prevalence. In 2010, it was estimated that PAD affected 202 million people globally, with                
those aged 75 or older having an approximately eight-fold risk compared to those aged less than                
60 (2, 3). Compounded by population ageing and an increase in the prevalence of diabetes, it was                 
estimated that the number of people living with PAD increased over the previous decade by 13%                
and 29% in high and low-middle income countries respectively (3). 
Symptomatic PAD typically presents as intermittent claudication (IC), defined as a reproducible            
ambulatory leg pain, in the calf and/or thigh and/or buttocks, caused by an oxygen              
supply-demand imbalance, relieved by rest (4, 5). As such, IC negatively impacts upon walking              
ability, functional capacity, quality of life (QoL), and daily activities, whilst also leading to a               
markedly increased mortality risk (6-11). The recommended treatment strategy for IC is            
non-invasive and includes pharmacological risk factor management and exercise therapy, via a            
supervised exercise programme (SEP) (12-14). SEPs should consist of a minimum of two hours              
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exercise per week for a 12-week period, with patients encouraged to exercise to the point of                
maximal pain (12). SEPs are supported by high-quality evidence for their clinical and cost              
effectiveness (15), with evidence also suggesting that SEP is equal to primary stenting for              
symptomatic improvement, which is maintained for a year after programme completion (16, 17). 
Despite the irrefutable evidence for the benefit of SEP, just 39% of UK vascular centres provide                
access to one (18), and for those that do, uptake and completion rates are suboptimal. One review                 
demonstrated that only 25% of screened patients are recruited to a programme (19), with time               
cited as the most common barrier for participation (20). Furthermore, the current            
recommendations for SEP appear to adopt a “​one size fits all” ​approach which is not based on                 
any objective measure of functional capacity, potentially limiting physiological and symptomatic           
benefits. One alternative that is both time-efficient and prescribed based on the gold-standard             
measure of cardiopulmonary exercise testing (CPET), is high-intensity, interval training (HIIT).           
HIIT therefore has the potential to overcome the previously cited programme-related drawbacks            
of traditional SEP. HIIT has demonstrated similar or superior benefits, when compared to             
traditionally prescribed exercise, in patients with coronary artery disease, chronic heart failure,            
hypertension, obesity and metabolic syndrome characteristics (21-24). HIIT has been highlighted           
as a potentially preferred treatment option in those with IC, though the evidence in this               
population is much more limited (20). Initial systematic review evidence has indicated that HIIT              
has the potential to provide clinical and symptomatic benefits, though there was significant             
heterogeneity between published studies in terms of HIIT modality, frequency, intensity, and            
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duration (25). The authors recommended that future appropriately designed studies consider           
shorter-term and low-volume HIIT programmes for patients with IC. 
Therefore, the aim of this multi-centre proof of concept study is to consider the safety,               
tolerability, feasibility, and acceptability of a short-term, low-volume HIIT programme in those            
with IC.  
 
Methods and analysis:  
INITIATE is a pragmatic, single-group, multicentre, and prospective interventional         
proof-of-concept study. The study design and inclusion / exclusion criteria have been informed             
by a previous, single-centre study including 30 patients (26). 
For this study, participants will be recruited consecutively and perform 6-weeks of HIIT. Study              
interventions and outcome assessments will be conducted by research staff that due to the nature               
of the study cannot be blinded. This protocol adheres to the Standard Protocol Items:              
Recommendations for Clinical Trials (SPIRIT) guidelines, and we used the SPIRIT checklist            
when writing this protocol (27, 28). 
Setting 
INITIATE will be conducted at two UK centres; (1) The Academic Vascular Surgical Unit, Hull               
Royal Infirmary, Kingston-Upon-Hull and (2) Atrium Health, Centre for Exercise & Health,            
Coventry and Warwickshire Hospitals NHS Trust, Coventry. Sponsorship is provided by Hull            
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University Teaching Hospitals NHS Trust and funding provided by the National Institute for             
Health Research, Research for Patient Benefit programme. Recruitment commenced in August           
2019, with a recruitment target of 40 patients (20 per site). Recruitment is anticipated to be                
completed by October 2020. 
Study registration 
The study was prospectively registered on clinicaltrials.gov (NCT04042311) and the study           
registration data set is given in table 1. Any amendments required to this protocol will seek                
approvals from the research ethics committee and will be outlined (with reasons) in the final               
published report. 
 
 
 
 
 
 
Table 1 – Study registration items 
Data category Information 
Primary registry and identifying number ClinicalTrials.gov 
NCT04042311 (Workstream 2) 
Date of registration in primary registry 01/08/19  
Source of monetary or material support National Institute for Health Research, 
Research for Patient Benefit programme 
Primary Sponsor Hull University Teaching Hospitals NHS 
Trust 
Contact for public queries JL (​Judith.Long@hey.nhs.uk​) 
Contact for scientific queries SP (​Sean.Pymer@hey.nhs.uk​) 
Public title high INtensity Interval Training In pATiEnts 
with intermittent claudication (INITIATE) 
Scientific title high INtensity Interval Training In pATiEnts 
with intermittent claudication (INITIATE): a 
multi-centre, proof-of-concept, prospective 
interventional study 
Countries of recruitment United Kingdom 
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Health condition or problem studied Intermittent Claudication 
Intervention High-intensity interval training 
Key inclusion and exclusion criteria Ages eligible for the study: ≥18 years 
Sexes eligible for the study: all 
Accepts healthy volunteers: No 
Inclusion criteria: 
Community dwelling adults aged 18 or over. 
ABPI <0.9 at rest or a drop of more than 
20mmHg after exercise testing 
Ability to walk unaided 
English speaking and able to comply with 
exercise instructions 
Exclusion Criteria: 
Unable to provide informed consent 
Critical limb threatening ischaemia / rest 
pain / tissue loss 
Active cancer treatment 
Significant comorbidities precluding safe 
participation in exercise testing and / or 
training according to the American College 
of Sports Medicine (ACSM) guidelines (28) 
Resting/uncontrolled tachycardia (>100bpm) 
and/or resting/uncontrolled hypertension 
(systolic blood pressure >180mmHg or 
diastolic blood pressure >100mmHg) 
Symptomatic hypotension 
Additional exclusion criteria: Exercise-induced myocardial ischaemia or 
significant haemodynamic compromise 
(manifesting as anginal symptoms, 
significant ECG changes or an abnormal 
blood pressure response). 
Study type Interventional  
Allocation: single group assignment 
Primary purpose: Treatment 
Date of first enrolment: 12/08/19 
Target sample size: 40 patients 
Recruitment status:  Recruiting  
Primary outcomes: Safety: occurrence of adverse and serious 
adverse events 
Feasibility: eligibility, recruitment and 
completion rates 
Tolerability: assessing reasons for 
withdrawal, and identifying ability to reach 
and maintain the required intensity. 
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Secondary outcomes: Acceptability: patient feedback via 
semi-structured interview 
pain-free and maximal walking distance 
quality of life 
cardiorespiratory measures 
ankle brachial pressure index 
 
How the sample will be selected 
This study will recruit patients with IC secondary to PAD referred to a usual-care SEP, with a                 
confirmed diagnosis of IC by resting and/or post exercise ankle-brachial pressure index (ABPI)             
and/or documented significant atherosclerosis on radiological imaging. 
Inclusion criteria: 
● Aged >18 years 
● ABPI <0.9 at rest or a systolic pressure drop of ≥20mmHg at the ankle after exercise                
testing 
● Ability to walk unaided 
● English speaking and able to comply with exercise instructions 
Exclusion criteria: 
● Unable to provide informed consent 
● Critical limb threatening ischaemia / rest pain / tissue loss 
● Active cancer treatment 
● Significant comorbidities precluding safe participation in exercise testing and / or training            
according to the American College of Sports Medicine (ACSM) guidelines (29) 
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● Resting/uncontrolled tachycardia (>100bpm) and/or resting/uncontrolled hypertension      
(systolic blood pressure >180mmHg or diastolic blood pressure >100mmHg) 
● Symptomatic hypotension 
Additional exclusion criteria: 
Following baseline CPET, patients will be withdrawn and prevented from continuing their            
involvement in the study if there is any evidence of: 
● Exercise-induced myocardial ischaemia or significant haemodynamic compromise       
(manifesting as anginal symptoms, significant ECG changes or an abnormal blood           
pressure response). 
Study Procedures: 
The participant pathway for the study is shown in Figure 1. Briefly, patients who are deemed                
eligible for a usual SEP will be referred to the research team and their medical history reviewed                 
to determine potential eligibility for INITIATE. Those appearing to meet the eligibility criteria             
will be sent an invitation letter and patient information sheet. Patients will then be contacted at                
least a week later via telephone to give them the opportunity to ask any questions and confirm if                  
they are willing to participate. Those who decide to participate will be asked to attend a baseline                 
visit where eligibility will be confirmed before informed consent is obtained. Those who decline              
the study will be offered SEP as per usual care.  
Acceptability of the study and intervention will be assessed using qualitative interviews. The             
participant information sheet and consent form will include a clause that outlines the conduction              
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of an interview with a subset of patients. The interview is optional, and participants can decline                
to be interviewed. Baseline and follow-up procedures will include a full and detailed medical              
history, medication and symptom review, assessment of ABPI and a Gardner-Skinner graded            
treadmill test (30), followed by post-exercise ABPI. For those who are confirmed eligible,             
spirometry and CPET will be subsequently undertaken. Quality of Life (QoL) measures will also              
be collected using the Medical Outcomes Study Short-Form 36 (SF-36) and the Kings College              
Hospitals Vascular QoL (VascuQoL) Questionnaires, both of which have demonstrated good           
reliability and validity in this patient population (31, 32). ​Following baseline CPET, exercise             
ECG and haemodynamic response will be evaluated to re-assess eligibility to undergo HIIT.             
Those who exhibit exercise-induced ischaemia or an abnormal haemodynamic response to           
volitional exhaustion will be withdrawn from the study and referred back to the vascular              
consultant/required specialty as appropriate. Given CPET is not part of routine care, all patients              
will sign informed consent prior to undergoing it. ​Measurements will be taken before starting the               
programme (baseline/week 0), immediately after completing the programme (week 6), then 12            
weeks later (week 18). A further follow-up will be conducted 4 weeks (week 10) after               
programme completion (at the Hull site only). 
 
 
Intervention 
This study will adapt a pragmatic and flexible HIIT protocol, based on a similar protocol               
currently being investigated in those with coronary artery disease (33). ​Patients will attend 3              
HIIT sessions per week for a period of 6 weeks, totalling 18 sessions. If participants miss                
sessions, the intervention period can be extended for up to 2 additional weeks to allow these                
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sessions to be completed. Those not completing 18 sessions over the extended 8-week period              
will be deemed to have satisfactorily completed the intervention as long as they have undertaken               
>80% of the HIIT sessions (i.e. ≥15 out of 18 sessions). All patients completing the allotted 6-8                 
weeks for the intervention (regardless of whether they have completed ≥ or <15 sessions) will be                
followed up. Those selecting to discontinue the intervention prematurely will be withdrawn, but             
the information collected up to their withdrawal will be retained and may still be used.  
The intervention will be performed using a cycle ergometer (Wattbike Trainer, Wattbike,            
Nottingham, UK), with exercise prescription based on the peak workload achieved during the             
cycle CPET at baseline. Variations from high to low intensity cycling will be achieved by               
altering the cycle cadence (rpm). Although walking is often the recommended mode of exercise              
for those with IC and a treadmill based HIIT programme has been previously considered (34,               
35), a cycle was chosen for the current investigation for a number of reasons. Firstly, the use of a                   
treadmill may preclude patients from reaching their prescribed HIIT training zones due to             
limiting claudication pain. Stationary cycling may also reduce the risk of falls, given the balance               
limitation often experienced by patients with IC (36). In addition, it has been demonstrated that               
the limiting symptoms during treadmill walking are often experienced in the leg, predominantly             
the calf, whereas the limiting symptoms during cycling are much more varied (37). Finally, it has                
also been noted that cycle testing is better tolerated than treadmill testing in those with IC, which                 
is important considering that the HIIT training zone requires the patient to exercise intermittently              
to near-peak exertion levels (38). 
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Our HIIT work to rest ratio will be 1:1 (one-minute high-intensity work interspaced with              
one-minute of low intensity work), with patients completing 10 intervals for an overall exercise              
session time of 20 minutes. If required, a titrated introduction to the HIIT programme will be                
used with fewer exercise intervals being completed in the first 2 weeks. Patients will also be                
allowed to complete less than 10 intervals for longer than the first 2 weeks if required but will be                   
encouraged to complete 10 as soon as possible thereafter. HIIT workloads will be set at 85-90%                
of the peak power output (PPO) achieved during the baseline CPET. Application of this              
workload aims to achieve 85-100% peak heart rate (HRpeak) from CPET by the end of the                
second interval. Our personal experience with cardiac patients has demonstrated that patients            
may exceed their peak heart rate (from baseline CPET) during HIIT sessions. This is also likely                
to be the case for those with IC, especially those who are unable to achieve a maximal effort                  
CPET. We will adopt a pragmatic approach to this by allowing it to occur without adjusting                
workload but monitoring on a case-by-case basis and will reduce cycling intensity when deemed              
appropriate. We will also record these occurrences to allow appropriate reporting. All sessions             
will be preceded and followed by a 10-minute warm-up and cool-down as is standard practice for                
exercise rehabilitation for older adults with chronic disease.  
Outcome Measures  
Primary Outcomes 
The primary outcomes for this study are safety, feasibility and tolerability.  
Safety will be assessed by determining the occurrence of any adverse or serious adverse events               
related to the intervention or study procedures. These events will be recorded in accordance with               
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the GCP decision tree for adverse event reporting and where applicable events will be reported to                
the sponsor and/or research ethics committee. 
Feasibility will be assessed by considering eligibility (​n = eligible/screened), recruitment (​n =             
recruited/eligible) and adherence (​n = recruited/completed). As such, the number of patients            
screened, recruited, commencing and completing (either satisfactorily or unsatisfactorily) the          
HIIT programme will be monitored at each site.  
Tolerability will be assessed by considering reasons for withdrawal (i.e. if they are related to the                
intervention) and identifying the number of patients able to reach and maintain the required              
intensity (i.e. ≥85% HRMax by the end of the second interval) for the full 10 intervals.                
Tolerability will also assess whether patients can complete the full 10 intervals by the end of the                 
second week.  
Secondary outcomes 
Secondary outcome measures include, acceptability, pain-free and maximal walking distance,          
ABPI, QoL and cardiorespiratory measures, collected during CPET.  
Acceptability will be assessed by conducting semi-structured interviews at both sites using a             
sample of patients in three groups:  
Group 1: Patients who are eligible for the study but decide not to participate (non-consenters).               
The interviews will explore reasons why patients chose not to participate in the study and               
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whether study material could be amended to be more appealing. As these patients have declined               
participation in the study, they will sign an interview specific consent form. 
Group 2: Those who agree to participate in, and complete, the exercise programme. The              
interviews will explore patient’s experiences of the HIIT programme, how acceptable they found             
it, whether they enjoyed it and whether they would be willing to undertake it again. They will                 
also be asked to provide information related to potential barriers to participation in the              
programme and study, and any changes they may feel are required. 
Group 3: Those who agree to participate but discontinued after at least one session. Patients will                
be asked about their reasons for discontinuation and what, if anything, could have been modified               
to prevent withdrawal from the study. 
An interview topic guide with a pre-determined set of open questions will be used but the                
interviews will be flexible to allow the interviewer to ask further probing questions based on               
patient responses, and for patients to raise issues not explicitly covered by the topic guide. All                
interviews will be audio recorded using a Dictaphone, transcribed verbatim and anonymised.  
Pain-free and maximal walking distance 
Pain-free and maximal walking distance will be determined using the Gardner/Skinner treadmill            
test which starts at 2.0 mp/h and 0% gradient, with gradient increasing by 2% every 2 minutes,                 
whilst the speed remains constant, up to a maximum of 15 minutes. ​For those unable to walk on                  
the treadmill at 2.0 mp/h the speed will be reduced, but this speed will remain consistent at all                  
follow-up visits to ensure standardisation. Patients will indicate when they begin to feel IC pain,               
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which will be recorded as pain-free walking distance and the patient will continue until the pain                
is too severe and they need to stop, which will be recorded as maximal walking distance. Patients                 
able to walk for 15 minutes will be excluded. 
Quality of Life 
QoL will be assessed with both a generic and disease specific questionnaire. The SF-36 will be                
used as it is recommended as the most appropriate generic tool for those with lower limb                
ischaemia (39). The SF-36 gives a scoring profile across 8 domains, ranging from 0 to 100, with                 
0 indicating worst possible health and 100 best possible health. Scales can also be combined to                
create a physical and mental component summary. 
The disease-specific questionnaire will be the VascuQoL which was designed for use in studies              
involving patients with lower limb ischaemia. It contains 25 items subdivided into 5 domains,              
which are rated on a 7-point scale with 1 representing the worst score and 7 the best. A sum                   
score is also calculated by dividing the total score by 25. 
Cardiorespiratory measures 
Cardiorespiratory function will be assessed at each timepoint using an individualised ramp based             
cycle CPET, conducted in accordance with international guidelines (40, 41). Patients will be             
screened for contraindications to CPET and continuously monitored for indications for           
termination as per the ACSM guidelines (29). The CPET will be preceded by a 3-minute period                
of rest on the bike to obtain resting measurements followed by a 3-minute reference period of                
unloaded cycling followed by a progressive individualised ramp protocol designed to elicit            
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volitional exhaustion within 8-12 minutes, concluding with a recovery period (41). Patients will             
be encouraged to maintain 65-70 rpm throughout the test until they are limited by volitional               
fatigue. Monitoring will be via 12-lead ECG, blood pressure, oxygen saturation and rating of              
perceived exertion (RPE). Attainment of a maximal effort will be considered if the patient              
achieves 2 out of the following 3 criteria; achieving ≥85% age-predicted maximum heart rate, a               
respiratory exchange ratio >1.10 and an RPE >17 (42). However, based on a previous study,               
≈25% of patients with IC are unable to achieve this, meaning it will not be applied as an                  
exclusion and patients will continue in the study, regardless of whether it is achieved (26)​.               
Breath-by-Breath gas analysis will be conducted (MedGraphics Ultima2 Medgraphics, St Paul,           
Minnesota, USA or Ergostick, LoveMedical, Manchester, UK) to allow determination of a            
number of cardiorespiratory fitness parameters.  
Ankle Brachial Pressure Index 
The systolic blood pressure will be measured bilaterally in the brachial, dorsalis pedis and              
posterial tibial arteries using a hand-held doppler and appropriately sized sphygmomanometer,           
with ABPI determined by dividing the higher ankle pressure of each leg with the highest arm                
pressure. Patients will be deemed eligible if they have an ABPI of <0.9 or a post-exercise                
systolic blood pressure drop at the ankle of ≥20 mmHg.  
Sample Size 
As this feasibility proof-of-concept study does not aim to make any statistical comparison nor              
estimate a standard deviation for future power calculations, there is no formal sample size              
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requirement. We aim to recruit 20 patients from each site over the recruitment period, for a total                 
of 40 patients. 
Data collection and management 
Data will be collected by the study team across 3/4 time-points dependant on site. Data will be                 
collected continuously for the qualitative study, based on the time at which patients decline,              
withdraw from or complete the intervention, until the point of data saturation. Data will be               
collected and retained in accordance with the General Data Protection Regulation (2018). All             
patients will be given a study code to ensure anonymity. Data will be stored via paper case report                  
forms (CRF) in code-secured research offices at the vascular laboratory in Hull Royal Infirmary              
and Coventry and Warwickshire University Hospital respectively with the same identification           
code. These CRF’s will be periodically scanned and sent to the team at Hull Royal Infirmary,                
who will manage the electronic and physical database, via email with end-to-end encryption.             
This database will be stored on a computer in the code-secured research office that is password                
protected and has both antivirus and firewall software. Only authorised members of the research              
team will have access to the patient data and transfer of data will be via Trust encrypted,                 
password protected USB devices or secure nhs.net mail. Only authorised members of the             
research team will have access to the final dataset which will be stored for five years following                 
study completion. 
Data Analysis 
Where applicability allows, the study will be reported in accordance with the Consolidated             
Standards of Reporting Trials (2010) statement extension to pilot and feasibility studies (43).             
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Descriptive statistics will be reported for our feasibility, tolerability and safety (proof of concept)              
outcomes. Descriptive statistics for our secondary outcomes will be reported to inform potential             
future studies in terms of clinical and QoL outcome measures.  
The qualitative data will be analysed using an inductive thematic analysis, whereby themes are              
identified from within the data (44). The researcher will read and re-read the transcripts to               
identify patterns of responses within the data that are related to the research question and can be                 
grouped together under a theme heading. The approach will be inductive, which means that the               
themes are data-driven, thus emerging from the data, and do not fit into a pre-existing coding                
frame  (44). 
Patient and Public Involvement 
The background Patient and Public Involvement (PPI) work for this study was supported by a               
grant from the NIHR Research Design Service Yorkshire and the Humber. Consequently, two             
focus group sessions, each involving five patients with a confirmed diagnosis of IC and              
experience of undertaking a standard SEP, were conducted which informed the design of this              
study. In addition, this PPI group is committed to continuous contribution during the research              
study, with the chair of the PPI group invited to attend all trial steering committee meetings. We                 
also aim to hold 3-4 PPI meetings over the course of the study to aid with addressing potential                  
recruitment or retention issues and aid with dissemination of the study findings.  
Ethics and Dissemination  
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Protocol approval was obtained via a local NHS research ethics committee (Bradford Leeds –              
18/YH/0112) and all patients will provide informed consent prior to participation, which will be              
obtained by study personnel with appropriate good clinical practice (GCP) training.  
Upon completion, study results will be published in peer-reviewed journals and presented at             
international scientific meetings. In addition, with our PPI group, we will disseminate findings to              
the public, which will include lay summaries to participants and vascular charities such as the               
Circulation Foundation (Registered Charity Number: 1102769). The expected impact for this           
study is the development of a new time-efficient exercise programme for patients with IC, which               
is more acceptable, thus improving uptake and adherence. Should this study support the             
feasibility of HIIT for patients with IC, we aim to undertake a multicentre, pilot randomised               
controlled trial comparing HIIT to standard SEPs, which can inform a definitive trial, which has               
potential to impact upon international guidelines. 
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